<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02418754</url>
  </required_header>
  <id_info>
    <org_study_id>R2176-3-AMD-1417</org_study_id>
    <nct_id>NCT02418754</nct_id>
    <nct_alias>NCT02603484</nct_alias>
  </id_info>
  <brief_title>Study of Intravitreal REGN2176-3 in Participants With Neovascular (&quot;Wet&quot;) Age-Related Macular Degeneration (AMD)</brief_title>
  <acronym>CAPELLA</acronym>
  <official_title>A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to explore the effect of REGN2176-3 on the Early&#xD;
      Treatment Diabetic Retinopathy Scale (ETDRS) best-corrected visual acuity (BCVA) in&#xD;
      participants with neovascular age-related macular degeneration (AMD), compared to&#xD;
      intravitreal aflibercept injection (IAI) monotherapy.&#xD;
&#xD;
      The secondary objectives of the study were the following:&#xD;
&#xD;
        -  To explore the effect of 2 dose levels of IVT REGN2176-3 on anatomical changes of CNV in&#xD;
           participants with nAMD compared to IAI monotherapy (at week 12)&#xD;
&#xD;
        -  To evaluate if short-term treatment with REGN2176-3 followed by IAI monotherapy offered&#xD;
           the same or additional benefit compared to continuous treatment with REGN2176-3. Also to&#xD;
           determine if there was benefit in initiating IAI treatment prior to REGN2176-3 compared&#xD;
           to continuous treatment with IAI.&#xD;
&#xD;
        -  To assess the safety and tolerability of IVT REGN2176-3 in participants with nAMD&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    No additional efficacy seen with REGN2176-3 over aflibercept alone&#xD;
  </why_stopped>
  <start_date type="Actual">May 5, 2015</start_date>
  <completion_date type="Actual">April 3, 2017</completion_date>
  <primary_completion_date type="Actual">August 17, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Week 12</time_frame>
    <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The anatomical state of the retinal vasculature of the study eye and the fellow eye was evaluated by funduscopic examination, fundus photography and FA to evaluate the total lesion area, CNV area, classic CNV area, and fluorescein leakage. CNV area values measured in square millimeters, each disc area was equivalent to 2.54 mm^2 on the retina; lower values represent better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>Total Lesion Size was assessed by Fluorescein Angiography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)</measure>
    <time_frame>Week 12</time_frame>
    <description>Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at Week 12 compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SHM was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">505</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>REGN2176-3 (1 mg: 2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN2176-3 (3 mg: 2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravitreal Aflibercept Injection (IAI) 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>REGN2176-3 (3 mg: 2 mg) to IAI 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. After Week 12, dosing was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IAI 2 mg to REGN2176-3 (3 mg:2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IAI every 4 weeks for 12 weeks. After Week 12, dosing was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REGN2176-3</intervention_name>
    <arm_group_label>IAI 2 mg to REGN2176-3 (3 mg:2 mg)</arm_group_label>
    <arm_group_label>REGN2176-3 (1 mg: 2 mg)</arm_group_label>
    <arm_group_label>REGN2176-3 (3 mg: 2 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Aflibercept Injection (IAI)</intervention_name>
    <arm_group_label>Intravitreal Aflibercept Injection (IAI) 2 mg</arm_group_label>
    <arm_group_label>REGN2176-3 (3 mg: 2 mg) to IAI 2 mg</arm_group_label>
    <other_name>Eylea®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Men or women ≥50 years of age&#xD;
&#xD;
          2. Active subfoveal CNV secondary to AMD as evidenced by FA in the study eye, as&#xD;
             determined by the reading center, including juxtafoveal lesions that affect the fovea&#xD;
&#xD;
          3. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye at the&#xD;
             screening visit&#xD;
&#xD;
          4. Provide signed informed consent&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Any prior treatment with anti-VEGF treatment in the study eye&#xD;
&#xD;
          2. Any prior treatment (ie, systemic or ocular treatment) with PDGF or PDGFR inhibitors&#xD;
&#xD;
          3. Dense fibrotic scar or atrophy in the study eye involving the center of the fovea&#xD;
&#xD;
          4. Presence of retinal pigment epithelial tears or rips involving the macula in the study&#xD;
             eye&#xD;
&#xD;
          5. Prior vitrectomy in the study eye&#xD;
&#xD;
          6. Any history of macular hole of stage 2 and above in the study eye&#xD;
&#xD;
          7. Any intraocular or periocular surgery within 3 months of day 1 in the study eye,&#xD;
             except lid surgery&#xD;
&#xD;
          8. History of corneal transplant in the study eye&#xD;
&#xD;
          9. Evidence of diabetic retinopathy or diabetic macular edema in either eye&#xD;
&#xD;
         10. Positive serum human chorionic gonadotropin/urine pregnancy test at the screening or&#xD;
             baseline visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arcadia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Asahikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 13, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2015</study_first_posted>
  <results_first_submitted>September 1, 2020</results_first_submitted>
  <results_first_submitted_qc>October 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 26, 2020</results_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 82 sites in US and 11 sites in Japan. A total of 804 participants were screened. Out of 804 participants, 505 were randomized and treated.</recruitment_details>
      <pre_assignment_details>Participants were initially randomized in a 1:2:2 ratio to receive REGN2176-3 (1 mg:2 mg) (REGN2176 1 mg:REGN3 2 mg) or REGN2176-3 (3 mg:2 mg) (REGN2176 3 mg:REGN3 2 mg) or 2 mg intravitreal aflibercept injection (IAI). One eye was under study (the fellow eye was assessed for safety only).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
          <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
          <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
          <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mg</title>
          <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 4 was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="P5">
          <title>Group 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg)</title>
          <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 5 was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Day 1 to Week 12)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="200"/>
                <participants group_id="P3" count="202"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="200"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2 (Day 1 to Week 52/End of Study)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="71"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Un-specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline population included all randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
          <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
          <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
          <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="200"/>
            <count group_id="B3" value="202"/>
            <count group_id="B4" value="505"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.2" spread="8.01"/>
                    <measurement group_id="B2" value="78.6" spread="8.77"/>
                    <measurement group_id="B3" value="77.7" spread="8.61"/>
                    <measurement group_id="B4" value="78.3" spread="8.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="317"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="491"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="186"/>
                    <measurement group_id="B4" value="473"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="193"/>
                    <measurement group_id="B3" value="194"/>
                    <measurement group_id="B4" value="485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12</title>
        <description>Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Full analysis set (FAS) that included all randomized participants who received any study treatment, had a baseline measurement of BCVA, and at least 1 post-baseline assessment of BCVA. Last observation carried forward (LOCF) method was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
            <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Best Corrected Visual Acuity (BCVA) of the Study Eye at Week 12</title>
          <description>Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. Change from baseline calculated by subtracting baseline value from observed post-baseline value at Week 12.</description>
          <population>Full analysis set (FAS) that included all randomized participants who received any study treatment, had a baseline measurement of BCVA, and at least 1 post-baseline assessment of BCVA. Last observation carried forward (LOCF) method was used to impute missing data.</population>
          <units>Letters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="1.01"/>
                    <measurement group_id="O2" value="5.7" spread="0.73"/>
                    <measurement group_id="O3" value="7.4" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To control for the family-wise type I error rate of 5%, for each of the 2 REGN2176-3 groups the 2-sided hypothesis comparing REGN2176-3 (1 mg: 2 mg) vs. Intravitreal Aflibercept Injection (IAI) 2 mg was tested at a significance level of α = 2.5%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Analysis was performed using analysis of covariance (ANCOVA) model with baseline measurements as covariate and treatment group, baseline angiographic choroidal neovascularization (CNV) subtype (predominantly or minimally classic versus occult versus occult with no classic lesions) as fixed factors.</non_inferiority_desc>
            <p_value>0.2052</p_value>
            <p_value_desc>Threshold for significance at 0.025 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>-1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.37</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>To control for the family-wise type I error rate of 5%, for each of the 2 REGN2176-3 groups the 2-sided hypothesis comparing REGN2176-3 (1 mg: 2 mg) vs. Intravitreal Aflibercept Injection (IAI) 2 mg was tested at a significance level of α = 2.5%.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Analysis was performed using ANCOVA model with baseline measurements as covariate and treatment group, baseline angiographic choroidal neovascularization (CNV) subtype (predominantly or minimally classic versus occult versus occult with no classic lesions) as fixed factors.</non_inferiority_desc>
            <p_value>0.0982</p_value>
            <p_value_desc>Threshold for significance at 0.025 level.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>-1.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.00</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)</title>
        <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on FAS. LOCF method was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
            <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Central Subfield Retinal Thickness (CST) at Week 12, as Measured by Optical Coherence Tomography (OCT)</title>
          <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.</description>
          <population>Analysis was performed on FAS. LOCF method was used to impute missing data.</population>
          <units>Microns</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-131.1" spread="6.88"/>
                    <measurement group_id="O2" value="-116.9" spread="4.96"/>
                    <measurement group_id="O3" value="-134.4" spread="4.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)</title>
        <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on FAS. LOCF method was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
            <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Resolution of Intraretinal and Subretinal Fluid From Baseline at Week 12 Measured by Optical Coherence Tomography (OCT)</title>
          <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation.</description>
          <population>Analysis was performed on FAS. LOCF method was used to impute missing data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.0"/>
                    <measurement group_id="O2" value="24.0"/>
                    <measurement group_id="O3" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)</title>
        <description>The anatomical state of the retinal vasculature of the study eye and the fellow eye was evaluated by funduscopic examination, fundus photography and FA to evaluate the total lesion area, CNV area, classic CNV area, and fluorescein leakage. CNV area values measured in square millimeters, each disc area was equivalent to 2.54 mm^2 on the retina; lower values represent better outcomes.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on FAS. LOCF was used to impute missing data. Here, number of participants analyzed = participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
            <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 12 Measured by Fluorescein Angiography (FA)</title>
          <description>The anatomical state of the retinal vasculature of the study eye and the fellow eye was evaluated by funduscopic examination, fundus photography and FA to evaluate the total lesion area, CNV area, classic CNV area, and fluorescein leakage. CNV area values measured in square millimeters, each disc area was equivalent to 2.54 mm^2 on the retina; lower values represent better outcomes.</description>
          <population>Analysis was performed on FAS. LOCF was used to impute missing data. Here, number of participants analyzed = participants with available data for this outcome measure.</population>
          <units>Square Millimeter (mm^2)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="0.44"/>
                    <measurement group_id="O2" value="-2.0" spread="0.31"/>
                    <measurement group_id="O3" value="-3.6" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)</title>
        <description>Total Lesion Size was assessed by Fluorescein Angiography.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on FAS. LOCF was used to impute missing data. Here, number of participants analyzed = participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
            <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Lesion Size at Week 12 Measured by Fluorescein Angiography (FA)</title>
          <description>Total Lesion Size was assessed by Fluorescein Angiography.</description>
          <population>Analysis was performed on FAS. LOCF was used to impute missing data. Here, number of participants analyzed = participants with available data for this outcome measure.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="0.43"/>
                    <measurement group_id="O2" value="-2.1" spread="0.31"/>
                    <measurement group_id="O3" value="-3.5" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)</title>
        <description>Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at Week 12 compared with baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on FAS. LOCF was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
            <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Gained At Least 15 Letters in BCVA From Baseline at Week 12, Measured by 4-meter Early Treatment Diabetic Retinopathy Scale (ETDRS)</title>
          <description>Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at 4 meters. BCVA score was measured using an eye chart and was reported as the number of letters read correctly at a testing distance of 4 meters using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at Week 12 compared with baseline.</description>
          <population>Analysis was performed on FAS. LOCF was used to impute missing data.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)</title>
        <description>SHM was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on FAS. LOCF was used to impute missing data. Here, number of participants analyzed = participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
            <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Subretinal Hyperreflectivity Material (SHM) at Week 12 Measured by Optical Coherence Tomography (OCT)</title>
          <description>SHM was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement.</description>
          <population>Analysis was performed on FAS. LOCF was used to impute missing data. Here, number of participants analyzed = participants with available data for this outcome measure.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="191"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-50.0" spread="5.94"/>
                    <measurement group_id="O2" value="-41.9" spread="4.17"/>
                    <measurement group_id="O3" value="-48.8" spread="4.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)</title>
        <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on FAS. LOCF was used to impute missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
            <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
            <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Central Retinal/Lesion Thickness at Week 12 Measured by Optical Coherence Tomography (OCT)</title>
          <description>CST was assessed using spectral domain optical coherence tomography (SD-OCT), a non-invasive diagnostic system providing high-resolution imaging sections of the retina. SD-OCT was performed in the study eye after pupil dilation. A negative change from baseline indicated improvement. Change from baseline calculated by subtracting baseline value from LOCF post-baseline value at Week 12.</description>
          <population>Analysis was performed on FAS. LOCF was used to impute missing data.</population>
          <units>Microns</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="200"/>
                <count group_id="O3" value="202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-150.7" spread="7.40"/>
                    <measurement group_id="O2" value="-139.6" spread="5.32"/>
                    <measurement group_id="O3" value="-160.4" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 52) regardless of seriousness or relationship to investigational product.</time_frame>
      <desc>Reported AEs are treatment-emergent and are defined as AEs starting after the first study eye injection and no later than 30 days after the last study eye or fellow eye injection. Analysis was performed on safety analysis set (SAF) and included all initially randomized participants who received any study drug before Week 12; it was based on Week 12 secondary randomization group assignment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: REGN2176-3 (1 mg:2 mg)</title>
          <description>Intravitreal injection of REGN2176-3 (REGN2176 1 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, Group 1 continued without a secondary randomization. After Week 12, dosing in Group 1 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: REGN2176-3 (3 mg:2 mg)</title>
          <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 2 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: Intravitreal Aflibercept Injection (IAI) 2 mg</title>
          <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 3 was monthly up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="E4">
          <title>Group 4: REGN2176-3 (3 mg:2 mg) to IAI 2 mg</title>
          <description>Intravitreal injection of REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 2 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 4 was monthly with IAI 2 mg up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
        <group group_id="E5">
          <title>Group 5: IAI 2 mg to REGN2176-3 (3 mg:2 mg)</title>
          <description>IAI every 4 weeks for 12 weeks. At Week 12, a secondary randomization occurred in Group 3 for those participants who completed the Week 12 assessments. After Week 12, dosing in Group 5 was monthly with REGN2176-3 (REGN2176 3 mg and REGN3 2 mg) up to Week 28, then criteria based re-dosing from Week 28-52.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Blindness transient</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Open angle glaucoma</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Non-Cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Impacted fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Non-Small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage ii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Basal ganglia stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="106"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="108"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="94"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E4" events="13" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E5" events="12" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Neovascular age-related macular degeneration</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="106"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <description>Study eye</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E5" events="15" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <description>Fellow eye</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E5" events="17" subjects_affected="13" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator has the right to independently publish study results from the investigator's site after a multi-center publication, or a defined period after the completion of the study by all sites. The investigator must provide the sponsor a copy of any such publication derived from the study for review and comment in advance of any submission, and delay publication, if requested, to allow the Sponsor to preserve its proprietary rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Administrator</name_or_title>
      <organization>Regeneron Pharmaceuticals, Inc.</organization>
      <phone>844-734-6643</phone>
      <email>clinicaltrials@regeneron.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

